Aralez and CAAIF Research Grant in Allergic Rhinitis- Letter of Intent (LOI)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with Unit
Memorial Deadline: RGCS review not required for LOI submission
External Deadline: Thursday 24th, September 2020
Description
ABOUT CAAIF
The Canadian Asthma, Allergy and Immunology Foundation (CAAIF) is a charitable foundation whose mission is to invest in research leading to new and better treatments that improve the lives of Canadians living with allergy, asthma and immunologic diseases.
ABOUT ARALEZ PHARMACEUTICALS CANADA INC.
Aralez Pharmaceuticals Canada Inc. is a leading Canadian specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products primarily in allergy, dermatology and other specialty areas.
GRANT OBJECTIVE
The objective of the CAAIF/Aralez Pharmaceuticals Canada Inc. Research Grant in Allergic Rhinitis is to fund a research grant focused on the area of allergic rhinitis.
VALUE OF THE AWARD
The maximum value of the award is $25,000.
Requirements
APPLICATION PROCESS
There will be a two stage application and review process.
1) Letter of Intent
A multidisciplinary peer review committee consisting of researchers, clinicians, healthcare providers and patients, will be assembled to review the Letter of Intent for relevance. Applications are due Thursday, September 24 at 11:59 pm EST.
2) Full Application
Selected applicants will be invited to submit a full application for scientific peer review by experts in the field.
More information can be found here.